Opinion|Videos|October 7, 2024

PSMA PET Imaging and Radioligand Therapy in mCRPC: Insights From VISION and TheraP Trials

Key Takeaways

Neal Shore, MD, FACS, discusses how the patient profile in the VISION trial, which involved progression on multiple therapies, reflects typical cases for Lutetium-177 treatment, emphasizing the crucial role of PSMA PET imaging in determining treatment suitability.